Eisai Co., Ltd.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Haruo Naito
- Full Time Employees
- 10,543
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 4-6-10, Koishikawa Tokyo TY Japan 112-8088
- IPO Date
- Feb 2, 2023
- Website
- eisai.com
- Similar Companies
- Business
- Eisai Co., Ltd. (ESAIY) develops, manufactures and markets prescription pharmaceuticals with a primary focus on neurology and oncology therapeutics. The company offers anti-epileptic drugs including Fycompa (perampanel) for partial onset and primary generalized tonic-clonic seizures; Alzheimer's disease treatments led by Leqembi (lecanemab) in partnership with Biogen; migraine therapies such as Aubagio (teriflunomide); and oncology products including Lenvima (lenvatinib) for various cancers; alongside supportive care solutions for neglected tropical diseases like lymphatic filariasis. Eisai operates an integrated model encompassing research, development, manufacturing and global marketing, serving patients and healthcare providers across neurology, oncology and other unmet medical needs areas. Founded in 1941 and headquartered in Tokyo, Japan, the company maintains R&D sites in Japan, the United States, United Kingdom and Singapore; production facilities in Japan, China, India, Indonesia, United States and United Kingdom; and sales subsidiaries in over 40 countries spanning the Americas, Europe, Asia, Africa and Oceania. Recent developments include the March 2025 tender offer to acquire EcoNaviSta Inc., following a July 2024 business alliance, to integrate its "Life Rhythm Navi" elderly monitoring SaaS into Eisai's dementia platform for enhanced prevention and early detection capabilities; a December 2024 memorandum of understanding with Fujirebio for diagnostic collaborations; a February 2025 licensing agreement with SciClone Pharmaceuticals subsidiary for drug commercialization; ongoing commitment of JPY 625 million to the GHIT Fund through FY2027 for infectious disease medicines in developing countries; and a 2024 share buyback of up to 6.5 million shares for JPY 30 billion to optimize capital structure.
FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug
Eisai Co., Ltd. (ESAIY) Analyst/Investor Day Transcript
Eisai Co., Ltd. (ESAIY) Q4 2026 Earnings Call Transcript
Merck-Eisai's combination cancer therapy fails to meet main goals of late-stage study
These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.
Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer's Disease at the 78th American Academy of Neurology's Annual Meeting
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
Eisai Co., Ltd. (ESAIY) Q3 2026 Earnings Call Transcript
Eisai Co., Ltd. (ESAIY) Discusses Value Creation Initiatives, ESG, and Dementia Area Contributions Transcript
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
Eisai Co., Ltd. (ESAIY) Q2 2026 Earnings Call Transcript
Merck, Eisai discontinue late-stage study for liver cancer therapy
Merck-Eisai's cancer drug combo meets one main goal in late-stage study
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
Eisai Co., Ltd. (ESAIY) Discusses On Latest Data On Lemborexant And Novel Orexin Receptor Agonist E2086 At The World Sleep 2025 Transcript
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug
Eisai Co., Ltd. (ESALF) Q1 2026 Earnings Call Transcript